Friday, 20 Oct 2017

You are here

Kids with Crohn's have Profound MSK Deficits - but No Increase in Fractures

Crohn’s disease (CD), a chronic inflammatory condition of the gastrointestinal tract, is also known for its propensity to affect the musculoskeletal system. Extraintestinal complications of CD include inflammatory polyarthritis, loss of muscle mass, growth retardation and vertebral compression fractures. Some of these are direct results of inflammation or indirect effects of malnutrition.

As it is not well understood whether medications used to treat CD may contribute to MSK complications, a cross-sectional study was conducted at the Children's Hospital of Eastern Ontario to evaluate impact the disease has on musculoskeletal health of children with newly diagnosed CD, before treatments were introduced.

A comprehensive examination was performed to assess for muscle mass and strength, and vertebral compression fractures. A total of 73 children with newly diagnosed CD (moderate to severe disease 90.4%, median disease duration 155 days) were assessed 4 days after treatment initiation; 36% of participants were prepubertal, with median PCDAI of 47 (SD14).

Mean height, weight and BMI in the study group was lower comparing to healthy adults with no difference  between bone age and chronological age, assuming normal skeletal maturation.

Jumping mechanograpy revealed low maximal peak muscle jump power in the single two-legged jump (-2.2 Mean Z-score (1.5 SD), p<0.01).

DEXA evaluations were notable for low total body mineral content (-1.5 (1.0SD), p<0.0001). With that, only 1 out of 70 patients with a spine radiograph had a vertebral fracture. In that particular case, there were no musculoskeletal abnormalities that could explain the fracture (LS BMD, height and BMI above average with Z-scores of + 0.4, +0.4 and +1.4 respectively).

The study concluded that despite profound muscle and bone deficits in children with newly diagnosed Crohn’s disease, the prevalence of vertebral fractures is very low. Short-term glucocorticoid therapy was associated with improved muscle strength in this cohort.

The relashionships among the disease state itself, magnitude of chronic steroid exposure and the pattern of bone morbidity merits further investigation.

Add new comment

More Like This

Zilretta - a New Drug FDA Approved for Osteoarthritis of the Knee

Flexion Therapeutics announced friday that the U.S. Food and Drug Administration (FDA) has approved its osteoarthritis (OA) of the knee injectable steroid drug Zilretta with the indication of moderate-to-severe knee pain.

Zilretta is the commonly used triamcinolon acetonide combined with a drug delivery system designed to provide extended pain relief over three months.

UAB Researchers Shed Light on Age-Related Osteoporosis

Researchers from the University of Alabama at Birmingham (UAB) have detailed mechanisms leading to age-related bone loss and osteoporosis.

Osteoporotic Fractures as Back Pain in Older Men

The Journal of Bone and Mineral Research reports that older men with undiagnosed vertebral fractures are likely to report new or worsening back pain. (Citation source

Romosuzumab Followed by Alendronate is Best in Fracture Prevention

The NEJM reports that in high risk post-menopausal women, romosozumab for 12 months followed by alendronate resulted in a significantly lower fracture than alendronate alone. 

Bad Knees Through the Ages

The average American today is twice as likely to be diagnosed with knee osteoarthritis as in the years before World War II, Harvard scientists say. And the reasons are less clear than you might think.

Based on a study of more than 2,000 skeletons from cadaveric and archaeological collections across the United States, a Harvard report is the first to definitively show that knee osteoarthritis prevalence has dramatically increased in recent decades.